CN113773333A - 抗癌剂及其制备 - Google Patents
抗癌剂及其制备 Download PDFInfo
- Publication number
- CN113773333A CN113773333A CN202110798234.5A CN202110798234A CN113773333A CN 113773333 A CN113773333 A CN 113773333A CN 202110798234 A CN202110798234 A CN 202110798234A CN 113773333 A CN113773333 A CN 113773333A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- compound
- formula
- independently selected
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Catalysts (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Pyrane Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361906133P | 2013-11-19 | 2013-11-19 | |
| US61/906,133 | 2013-11-19 | ||
| CN201480070416.9A CN105829299A (zh) | 2013-11-19 | 2014-11-19 | 抗癌剂及其制备 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201480070416.9A Division CN105829299A (zh) | 2013-11-19 | 2014-11-19 | 抗癌剂及其制备 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113773333A true CN113773333A (zh) | 2021-12-10 |
Family
ID=53180106
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110798232.6A Pending CN113461705A (zh) | 2013-11-19 | 2014-11-19 | 抗癌剂及其制备 |
| CN201480070416.9A Pending CN105829299A (zh) | 2013-11-19 | 2014-11-19 | 抗癌剂及其制备 |
| CN202110798234.5A Pending CN113773333A (zh) | 2013-11-19 | 2014-11-19 | 抗癌剂及其制备 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110798232.6A Pending CN113461705A (zh) | 2013-11-19 | 2014-11-19 | 抗癌剂及其制备 |
| CN201480070416.9A Pending CN105829299A (zh) | 2013-11-19 | 2014-11-19 | 抗癌剂及其制备 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US10000505B2 (enExample) |
| EP (1) | EP3071563B1 (enExample) |
| JP (2) | JP6937578B2 (enExample) |
| KR (1) | KR102428737B1 (enExample) |
| CN (3) | CN113461705A (enExample) |
| AU (1) | AU2014353087B2 (enExample) |
| BR (1) | BR112016011430B1 (enExample) |
| CA (1) | CA2931111C (enExample) |
| CL (1) | CL2016001209A1 (enExample) |
| DK (1) | DK3071563T3 (enExample) |
| EA (1) | EA035262B1 (enExample) |
| ES (1) | ES2943711T3 (enExample) |
| FI (1) | FI3071563T3 (enExample) |
| IL (2) | IL282430B2 (enExample) |
| MX (1) | MX375896B (enExample) |
| MY (1) | MY189459A (enExample) |
| PE (1) | PE20161240A1 (enExample) |
| PH (2) | PH12021551085A1 (enExample) |
| PT (1) | PT3071563T (enExample) |
| WO (1) | WO2015077370A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA035262B1 (ru) | 2013-11-19 | 2020-05-21 | Пюрдью Рисёрч Фаундейшн | Противораковые агенты и их получение |
| JP2019524650A (ja) * | 2016-06-08 | 2019-09-05 | ウィリアム マーシュ ライス ユニバーシティWilliam Marsh Rice University | タイランスタチンaの誘導体、それについての治療方法および合成方法 |
| CA3037883A1 (en) | 2016-09-23 | 2018-03-29 | Purdue Research Foundation | Anti-cancer agents and preparation thereof |
| CN111788208B (zh) | 2017-09-20 | 2023-11-24 | Ph制药有限公司 | 泰兰他汀类似物 |
| CN109020876A (zh) * | 2018-09-21 | 2018-12-18 | 大连理工大学 | 一种新型6-羟基-2h-二氢吡啶-3-酮的制备方法 |
| JP2023521135A (ja) * | 2020-04-09 | 2023-05-23 | ブリストル-マイヤーズ スクイブ カンパニー | メアヤマイシン類似体および使用方法 |
| CN113563361B (zh) * | 2021-08-17 | 2022-05-20 | 浙江珲达生物科技有限公司 | 一种从伯克霍尔德菌发酵液提取fr901464的方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110086909A1 (en) * | 2006-09-08 | 2011-04-14 | University Of Pittsburgh-- Of The Commonwealth System Of Higher Education | Synthesis of fr901464 and analogs with antitumor activity |
| CN103261398A (zh) * | 2010-02-25 | 2013-08-21 | 马罗内生物创新公司 | 伯克霍尔德氏菌属的分离细菌菌株及其农药代谢物 |
| WO2014068443A1 (en) * | 2012-11-05 | 2014-05-08 | Pfizer Inc. | Spliceostatin analogs |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901464A (fr) | 1943-01-23 | 1945-07-27 | Boehringer & Soehne Gmbh | Procédé d'obtention de vanilline |
| HUE025507T2 (en) | 2008-03-18 | 2016-02-29 | Genentech Inc | Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use |
| IN2014MN00242A (enExample) * | 2011-08-27 | 2015-09-25 | Marrone Bio Innovations Inc | |
| EA035262B1 (ru) | 2013-11-19 | 2020-05-21 | Пюрдью Рисёрч Фаундейшн | Противораковые агенты и их получение |
-
2014
- 2014-11-19 EA EA201691010A patent/EA035262B1/ru not_active IP Right Cessation
- 2014-11-19 FI FIEP14863201.1T patent/FI3071563T3/fi active
- 2014-11-19 PE PE2016000653A patent/PE20161240A1/es unknown
- 2014-11-19 ES ES14863201T patent/ES2943711T3/es active Active
- 2014-11-19 PT PT148632011T patent/PT3071563T/pt unknown
- 2014-11-19 CN CN202110798232.6A patent/CN113461705A/zh active Pending
- 2014-11-19 AU AU2014353087A patent/AU2014353087B2/en active Active
- 2014-11-19 CN CN201480070416.9A patent/CN105829299A/zh active Pending
- 2014-11-19 CA CA2931111A patent/CA2931111C/en active Active
- 2014-11-19 WO PCT/US2014/066458 patent/WO2015077370A1/en not_active Ceased
- 2014-11-19 KR KR1020167016232A patent/KR102428737B1/ko active Active
- 2014-11-19 IL IL282430A patent/IL282430B2/en unknown
- 2014-11-19 MX MX2016006591A patent/MX375896B/es active IP Right Grant
- 2014-11-19 DK DK14863201.1T patent/DK3071563T3/da active
- 2014-11-19 MY MYPI2016000932A patent/MY189459A/en unknown
- 2014-11-19 US US15/038,027 patent/US10000505B2/en active Active
- 2014-11-19 EP EP14863201.1A patent/EP3071563B1/en active Active
- 2014-11-19 PH PH1/2021/551085A patent/PH12021551085A1/en unknown
- 2014-11-19 JP JP2016532025A patent/JP6937578B2/ja active Active
- 2014-11-19 BR BR112016011430-2A patent/BR112016011430B1/pt active IP Right Grant
- 2014-11-19 CN CN202110798234.5A patent/CN113773333A/zh active Pending
-
2016
- 2016-05-15 IL IL245637A patent/IL245637B/en active IP Right Grant
- 2016-05-19 CL CL2016001209A patent/CL2016001209A1/es unknown
- 2016-05-19 PH PH12016500924A patent/PH12016500924A1/en unknown
-
2019
- 2019-07-05 JP JP2019125655A patent/JP6929903B2/ja active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110086909A1 (en) * | 2006-09-08 | 2011-04-14 | University Of Pittsburgh-- Of The Commonwealth System Of Higher Education | Synthesis of fr901464 and analogs with antitumor activity |
| CN103261398A (zh) * | 2010-02-25 | 2013-08-21 | 马罗内生物创新公司 | 伯克霍尔德氏菌属的分离细菌菌株及其农药代谢物 |
| WO2014068443A1 (en) * | 2012-11-05 | 2014-05-08 | Pfizer Inc. | Spliceostatin analogs |
Non-Patent Citations (2)
| Title |
|---|
| ARUN K. GHOSH等: "Enantioselective Syntheses of FR901464 and Spliceostatin A: Potent Inhibitors of Spliceosome", ORGANIC LETTERS, vol. 15, no. 19, 19 September 2013 (2013-09-19), pages 5088 - 5091, XP055344459, DOI: 10.1021/ol4024634 * |
| SAMI OSMAN等: "Structural Requirements for the Antiproliferative Activity of Pre-mRNA Splicing Inhibitor FR901464", CHEM. EUR. J., vol. 17, 19 November 2010 (2010-11-19), pages 895 - 904, XP055356284, DOI: 10.1002/chem.201002402 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6929903B2 (ja) | 抗癌剤およびその調製方法 | |
| US12435071B2 (en) | Bryostatin compounds and methods of preparing the same | |
| JP7641933B2 (ja) | カリスポンジオリド、その類似体、およびそれらの使用 | |
| HK40062614A (en) | Anti-cancer agents and preparation thereof | |
| WO2013079017A1 (zh) | 2-位烷基或芳香基取代的丹参酮衍生物、及其制备方法和应用 | |
| HK1227866A1 (en) | Anti-cancer agents and preparation thereof | |
| HK1227866B (en) | Anti-cancer agents and preparation thereof | |
| CN108026084A (zh) | 治疗化合物及其使用方法 | |
| JP7111722B2 (ja) | 抗がん剤およびその調製方法 | |
| NZ721152B2 (en) | Anti-cancer agents and preparation thereof | |
| NZ759166B2 (en) | Anti-cancer agents and preparation thereof | |
| WO2022040788A1 (en) | Open-ring and lactone derivatives of unsaturated trihydroxy c-18 fatty acids and pharmaceutical compositions thereof having anti-cancer activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20211210 |